Xybion Digital Inc. Stock

Equities

XYBN

CA98423T1093

Software

Market Closed - Toronto S.E. 11:00:00 2024-04-16 am EDT 5-day change 1st Jan Change
0.49 CAD 0.00% Intraday chart for Xybion Digital Inc. 0.00% -1.01%
Sales 2022 16.77M 23.11M Sales 2023 16.44M 22.66M Capitalization 75.12M 104M
Net income 2022 - 0 Net income 2023 -1M -1.38M EV / Sales 2022 6.55 x
Net cash position 2022 7.48M 10.31M Net cash position 2023 4.39M 6.05M EV / Sales 2023 4.3 x
P/E ratio 2022
-120 x
P/E ratio 2023
-56.5 x
Employees -
Yield 2022
0.22%
Yield 2023
-
Free-Float 2.9%
More Fundamentals * Assessed data
Dynamic Chart
Envol Biomedical selects Xybion?s Preclinical Gold Standard LIMS, Pristima, to Digitize Lab Operations CI
Xybion Digital Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Xybion Digital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Xybion Digital Closes Purchase of Autoscribe, US$15 Million Credit Facility MT
Xybion Digital Inc. Announces USD 15 Million Credit Facility CI
Xybion Digital Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Xybion Digital Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Deciphex and Xybion Digital Inc. Join forces to Infuse the Power of Micropathology Digital Slide Reading into Dynamic Non-clinical Study LIMS Workflows CI
Certara, Inc. and Xybion Digital Inc. Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & Efficacy CI
Xybion to Streamline, Digitize and Optimize Stability Study Operations and Improve Compliance Using Labwise XD LIMS Platform CI
Xybion Digital Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Hubei Topgene Xingsheng Partners with Xybion Digital Inc. to Drive Medical Innovation Using Xybion Preclinical Solution, Pristima Xd CI
Xybion Digital Maintained at Buy as FQ3 Results Come in Weaker than Expected; Price Target Lowered to C$3.15 MT
Xybion Digital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Xybion Digital Announced Proposed Financing of Up to $5 Million MT
More news
Current month+8.89%
1 month+8.89%
3 months+1.03%
6 months-23.44%
Current year-1.01%
More quotes
1 month
0.45
Extreme 0.45
0.49
Current year
0.42
Extreme 0.415
0.50
1 year
0.32
Extreme 0.32
1.40
3 years
0.32
Extreme 0.32
3.50
5 years
0.32
Extreme 0.32
3.50
10 years
0.32
Extreme 0.32
3.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-11-14
Director of Finance/CFO - 21-11-14
President - 18-03-31
Members of the board TitleAgeSince
Chief Executive Officer - 21-11-14
Director/Board Member 66 21-11-14
Director/Board Member - 21-11-14
More insiders
Date Price Change Volume

Delayed Quote Toronto S.E., April 16, 2024 at 11:00 am EDT

More quotes
Xybion Digital Inc. is a software as a service company, which digitizes drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a cloud platform. It offers solution through Pristima XD, Labwise XD, Xybion QMS, Emidence XD, and ECM XD. Its solutions focus on employee health and safety, integrated preclinical lab management, early-stage drug discovery, digital lab solutions, regulatory compliance, quality management, predictive compliance, content management, and systems validation. The Company help its customers with cloud-enabled Laboratory Information Management System (LIMS) software with embedded document management, data management, compliance, and safety modules. It serves industries, such as life sciences, healthcare and insurance, safety and workers comp, transportation, financial services, food and beverage, manufacturing, petrochemicals, radio pharmacy, biobanking, veterinary sciences, and materials and mining, among others.
More about the company

Quarterly revenue - Rate of surprise